Relay Therapeutics (RLAY) Current Deferred Revenue (2021 - 2024)

Relay Therapeutics (RLAY) has 4 years of Current Deferred Revenue data on file, last reported at $7.7 million in Q4 2024.

• Quarterly Current Deferred Revenue changed N/A year-over-year to $7.7 million in Q4 2024, while the trailing twelve-month figure through Dec 2024 was $7.7 million (changed N/A YoY) and the FY2024 annual result came in at $7.7 million, changed N/A from the prior year.
• Current Deferred Revenue advanced to $7.7 million in Q4 2024 per RLAY's latest filing, from $24000.0 in the prior quarter.
• Across five years, Current Deferred Revenue topped out at $7.7 million in Q4 2024 and bottomed at $15000.0 in Q2 2023.
• The 4-year median for Current Deferred Revenue is $207000.0 (2021), against an average of $1.1 million.
• The widest annual swing landed in 2022, when Current Deferred Revenue slumped 79.95%; it then tumbled 81.93% in 2023.
• Tracing RLAY's Current Deferred Revenue over 4 years: stood at $248000.0 in 2021, then sank by 66.53% to $83000.0 in 2022, then plunged by 71.08% to $24000.0 in 2023, then jumped by 31895.83% to $7.7 million in 2024.
• Per Business Quant, the three latest RLAY Current Deferred Revenue figures stand at $7.7 million (Q4 2024), $24000.0 (Q3 2023), and $15000.0 (Q2 2023).

Peer Comparison